Skip to main content
Evidence Snapshot

MAP kinase-interacting serine/threonine-protein kinase 1

CHEMBL4718 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:44Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4718
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats MAP kinase-interacting serine/threonine-protein kinase 1 as ChEMBL target CHEMBL4718, mapped to UniProt Q9BUB5. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
MAP kinase-interacting serine/threonine-protein kinase 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4718
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9BUB5
MAP kinase-interacting serine/threonine-protein kinase 1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why MAP kinase-interacting serine/threonine-protein kinase 1 matters

As of 2026-09-14

MAP kinase-interacting serine/threonine-protein kinase 1 is reviewed as MAP kinase-interacting serine/threonine-protein kinase 1 (UniProt Q9BUB5); the current evidence base includes 8 approved drugs, 2658 compounds, and 391 assays, with lead potency reaching pChEMBL 10.0.

Protein context
MAP kinase-interacting serine/threonine-protein kinase 1

MAP kinase-interacting serine/threonine-protein kinase 1 Sequence length is 465 aa.

Review this target as MAP kinase-interacting serine/threonine-protein kinase 1, mapped to UniProt Q9BUB5. Sequence length is 465 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt Q9BUB5 Protein
Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 8 approved drugs, 2658 compounds, and 391 assays for this target. The dominant activity type is IC50. CHEMBL5855544 is the current potency anchor at pChEMBL 10.0.

Use CHEMBL5855544 as the tractability anchor when discussing potency (pChEMBL 10.0).

Activity source · ChEMBL 36 via Core Engine
8 approved pChEMBL 10.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why MAP kinase-interacting serine/threonine-protein kinase 1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9BUB5, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2658
Total Compounds
391
Total Assays
8
Approved Drugs
IC50: 1968.0, KI: 54.0, KD: 122.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5855544
 10.0 IC50 —
No preferred name
CHEMBL4879010
 9.8 IC50 —
No preferred name
CHEMBL5984153
 9.5 IC50 —
No preferred name
CHEMBL6052925
 9.5 IC50 —
No preferred name
CHEMBL5844466
 9.4 IC50 —

Approved Drugs

Structure Compound First Approval
BRIGATINIB
CHEMBL3545311
 2017
VANDETANIB
CHEMBL24828
 2011
SORAFENIB
CHEMBL1336
 2005
ERLOTINIB
CHEMBL553
 2004
GEFITINIB
CHEMBL939
 2003
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:44Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4718